Published November 09, 2026 · Compiled from the F-1/A filed on SEC EDGAR on 2026-11-09 and the Quintarthai IPO calendar. Quoted passages are the filing's own words.

Windward Bio Group AG (WWB) IPO: what the F-1/A filing says

Windward Bio Group AG filed an F-1/A with the SEC on 2026-11-09 in connection with its US listing.

In the Quintarthai IPO calendar: status Upcoming, exchange -, expected listing date Nov 13, 2026.

Use of proceeds (quoted from the filing)

• “We estimate that our net proceeds from the sale of 10,294,117 common shares in this offering will be approximately $155.6 million, based on an assumed initial public offering price of $17.00 per share, which is the midpoint of our estimated offering price range set forth on the cover page of this prospectus, after deducting underwriting discounts, commissions and estimated expenses payable by us…”
• “If the underwriters exercise their option in full to purchase 1,544,117 additional common shares, our estimated net proceeds will be approximately $179.7 million, after deducting underwriting discounts, commissions and estimated expenses payable by us related to the offering.”
• “We also expect to receive net proceeds of approximately $48.2 million from the concurrent private placement with Sanofi, after deducting estimated private placement expenses, including placement agent fees, payable by us.”
• “The actual net proceeds payable to us will be determined based on the actual number of common shares sold by us, the actual initial public offering price and other terms of the offering determined at pricing.”
• “Our expected use of our net proceeds from this offering and the concurrent private placement represents our intentions based on our current plans and business conditions, which could change in the future as plans and conditions evolve.”

Source: F-1/A on SEC EDGAR · IPO research page: WWB.

Research and analysis only — not investment advice, not a recommendation to apply or avoid.